Search
You're invited to try out the new version of Value Research Online. Click here to begin: https://beta.valueresearchonline.com
Advice
Ask Value Research
Big Questions
Tax Q&A
The Plan
Columns
Econology
First Page
Generally Speaking
Guest Column
Mainstreet
Not Just Kidding
Of This & That...
Straight Talk
Taking Stock
The Chartist
Top of Mind
World Savings Day
Year of SIP
Fund Research
Category Watch
Fund Analysis
House Voice
IPO Analysis
Rating Radar
Stock Research
Data for Thought
Stock Advisor
Stock Analyst Choice
Stock Ideas
Stock Strategy
News & Commentary
Fund News
Fundwire
Marketwire
Newswire
Stockwire
Others
Advertorial
Book Review
Budget Special
First things...
Fund Focus
Fund Manager's View
Fundwise
How I did it
In Remembrance
Income Tax Know How
Insurance
Interview
Learning
Moneywise
Mutual Fund Sahi Hai
Omaha Live
SIP Sahi Hai
Special Report
Tax Saving Alternatives
Using Value Research Online
Vital Statistics
Words Worth

News & Views - Lupin

Bithi Patnaik's story is one of exploitation and mis-selling by banks, yet she chose not to lose hope and became an informed investor |
Here are some companies that have significantly grown and shrunk in size over the last 10 years |
Riding on a strong ANDA pipeline, benefits from generics and gains from Gavis, Lupin is expected to see its earnings compound at 30 per cent |
The pharma sector, which once used to be the star of the Street, has been witnessing bad times |
This comparison pits told old rivals against each other using MSCI India Indices. Time determines the answer |
An analysis of stock market transactions reveals that FIIs and domestic institutions are taking contrasting views on sectors |
The decline in healthcare shares reflects investor concerns about the likely impact on earnings |
An analysis of Rakesh Jhunjhunwala's portfolio shows that his average returns have been highest from the stocks he held the longest |
With high numbers of ANDAs, mid-rung pharma companies could outperform their larger peers in the future |
Lupin started as a TB specialist and grew itself over the years through acquisitions. Things went on so well that it made its shareholders as rich as Croesus |
Each of these companies has faced tough periods but each has overcome them. See what the future holds for these multibaggers |
Better operating leverage and product mix contributed to a significant jump in gross margins for Dr Reddy's in the September quarter |
Home | My Portfolio | ELSS | Funds | Investors' Hangout | Income | Insurance | Value Investing | Learn | Archive | Ask | We're Hiring | Subscribe | About Us | Log In | Free Sign Up